Physicians on Sermo weighed in on triple agonist adoption. 34% want more data. 38% say…
Sermo Physician Resources
Pharmaceuticals
Pharmaceutical advisory boards as a physician’s side gig
Learn how physicians join pharmaceutical advisory boards, how much they pay, and how doctors can…
Journavx FDA approval: non-opioid pain management in 2026
Journavx (suzetrigine) is the first new pain drug class in 20 years. Explore trial results,…
How AI is reshaping drug development in 2026: discovery to delivery
On Sermo, physicians explore how AI is transforming drug development, from rational design to predictive…
Opioid MDL accountability: prescribing risk and the CDC guidelines
Analyze how the Opioid MDL settlements and CDC guidelines are reshaping accountability and driving defensive…
Pharmacist moonlighting: Strategic clinical income strategies
Explore clinical moonlighting opportunities for pharmacists in hospital and remote settings for supplemental income.
Alternative career paths for pharmacists
Explore lucrative alternative careers for pharmacists in research, health tech, and many more high-earning fields.
How to create an effective HCP marketing strategy in 2026
Sermo's physician-only platform provides data-driven HCP marketing solutions for endless engagement and education opportunities. Join…
Pharmacists: Here’s how to earn extra income with paid surveys
Discover how pharmacists can earn extra income by answering paid surveys. Sign up for Sermo…
GLP-1s: Who’s in control, doctors or PBMs?
Sermo’s new report explores the tension between GLP-1 efficacy and access. Discover how PBMs and…
Lepodisiran: A new cholesterol drug raising big questions
Explore physician reactions to Lepodisiran, an RNA-based cholesterol drug showing a 94% reduction in Lp(a).…
What doctors really think about the cost of weight loss drugs
What do doctors think about the cost of weight loss drugs? Learn how cost, access,…